CombiMatrix' Announces CombiCore™ Access Program with the University of Colorado
News Jan 10, 2006
Acacia Research Corporation has announced that its CombiMatrix group has signed a non-exclusive agreement with The University of Colorado Health Sciences Center under the Company's CombiCore™ access program.
Under this agreement all University of Colorado researchers can purchase, through their microarray core facility, CombiMatrix' CustomArrays™ and CatalogArrays™, including array processing services performed at the University of Colorado Health Science Center Microarray Core Facility
"Our Core lab is dedicated to providing high-quality microarray laboratory instruction, service, and consultation to the research and clinical community affiliated with UCHSC and other research institutions throughout the nation," stated Dr. Bifeng Gao, the UCHSC Core Facility Manager.
"This program provides us an opportunity to support our customers with more microarray choices for their specific needs."
"The University of Colorado is one of the nation's largest academic consumers of microarrays," said Michael Tognotti, Vice President of Sales and Marketing of CombiMatrix.
"Now researchers can purchase our products through the UCHSC Core Facility, in addition to array processing services which include sample processing and data analysis."
"This agreement provides researchers with unique access to our products by enabling one of the world's most experienced Microarray Core Facilities providing complete array services and application training."
"CombiMatrix' CombiCore program is a special program designed to meet the unique needs of academic organizations, with core microarray facilities, that want broad access to CombiMatrix's DNA microarray technology," said Dr. Amit Kumar President and CEO of CombiMatrix.
"This program is designed to leverage the infrastructure that already exists at each university to market, sell and deliver products. We hope to add additional university core laboratories to our CombiCore program."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE